#USA #New York #Breast Cancer #minoxidil #Rogaine

New Study on Minoxidil Use in Breast Cancer Patients

As many women undergoing chemotherapy face distressing hair loss, a recent study sheds light on a potential solution. Hair loss can not only affect physical appearance but also significantly impact self-esteem, potentially leading to reduced confidence in pursuing necessary treatments. However, researchers at NYU Langone Health have explored the safety and effectiveness of low doses of oral minoxidil, a well-known hair loss treatment, in women battling breast cancer.

Minoxidil is more commonly recognized as the active ingredient in Rogaine, an over-the-counter product for hair regrowth. Traditionally prescribed for various forms of hair loss, it is known for its ability to dilate blood vessels. Consequently, concerns arose regarding its potential side effects during chemotherapy, including heart-related issues such as chest pain or shortness of breath. Nevertheless, the new findings suggest that when administered at low doses, minoxidil not only proves effective but does so without significant heart-related complications.

The study examined 51 breast cancer patients, including those who had undergone chemotherapy, surgery, or radiation. The results were promising. Approximately 76% of participants experienced either increased hair growth or stabilized hair loss within just three to six months of treatment. This is a significant finding, given the emotional toll that hair loss can take on cancer patients.

Devyn Zaminski, a medical student involved in the study, emphasized that their research should reassure breast cancer patients about the availability of a safe and effective method to manage their hair loss.